Loading...

Purified anti-mouse Ly-6C Antibody Purified anti-mouse Ly-6C Antibody

Pricing & Availability
Clone
HK1.4 (See other available formats)
Regulatory Status
RUO
Other Names
Lymphocyte antigen 6 complex, locus C
Isotype
Rat IgG2c, κ
Ave. Rating
Submit a Review
Product Citations
publications
HK1dot4_Pure_070808.jpg
C57BL/6 mouse bone marrow cells stained with purified HK1.4, followed by anti-rat IgG PE (gated on myeloid cell population)
  • HK1dot4_Pure_070808.jpg
    C57BL/6 mouse bone marrow cells stained with purified HK1.4, followed by anti-rat IgG PE (gated on myeloid cell population)
  • HK1dot4_Pure_Ly6c_Antibody_2_102518
    Fresh, frozen mouse spleen was stained with purified Ly6C clone HK1.4 conjugated and detected with a Cy5 CODEX™ oligonucleotide duplex (red). Samples were counterstained with TCR FITC (green). Data generated at Akoya Biosciences, Inc. using the CODEX™ technology.
Compare all formats
Cat # Size Price Quantity Check Availability Save
128001 50 µg DKK387
Check Availability


Need larger quantities of this item?
Request Bulk Quote
128002 500 µg DKK1396
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Most hematopoietic cells express one or more members of Ly-6 family. The expression of Ly-6 varies with development stage and activation. Ly-6C is a 14-17 kD GPI-linked surface protein expressed on mouse monocyte/macrophage cells, endothelial cells, neutrophils, and some T cell subsets. Ly-6C is reported to be an indicator of memory CD8+ T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
L3 cloned CTL cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F - Verified
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone HK1.4 does not block the binding of clone RB6-8C58.

Additional reported applications (for relevant formats of this clone) include: in vitro activation of T cells1-3 and immunohistochemistry of frozen sections4.

Application References
  1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (Activ)
  2. Herold KC, et al. 1990. Diabetes 39:815. (Activ)
  3. Havran WL, et al. 1988. J. Immunol. 140:1034 (Activ)
  4. Flanagan K, et al. 2008. J. Immunol. 180:3874. (IHC)
  5. Makaroff LE, et al. 2009. P. Natl. Acad. Sci. USA 106:4799. (FC)
  6. Zuber J, et al. 2009. Genes Dev. 23:877. (FC) PubMed
  7. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  8. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  9. Watson NB, et al. 2015. J Immunol. 194:2796. PubMed
Product Citations
  1. Li F, et al. 2020. EMBO J. 39:e103205. PubMed
  2. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  3. Blériot C, et al. 2020. Methods Mol Biol. 2164:87. PubMed
  4. Cai S, et al. 2020. Sci Rep. 10:14249. PubMed
  5. Calcagno DM, et al. 2020. Sci Immunol. 5: . PubMed
  6. Valet C, et al. 2022. J Clin Invest. 132: . PubMed
  7. Campisi L, et al. 2022. Nature. 606:945. PubMed
  8. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  9. Hezaveh K, et al. 2022. Immunity. 55:324. PubMed
  10. Potempa M, et al. 2022. J Immunol. 208:1742. PubMed
  11. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
  12. Filippini D, et al. 2019. Sci Rep. 9:12286. PubMed
  13. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  14. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  15. Bajaña S, et al. 2021. Front Immunol. 11:577718. PubMed
  16. Nobs SP, et al. 2021. J Allergy Clin Immunol. . PubMed
  17. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  18. Reglero-Real N, et al. 2021. Immunity. :. PubMed
  19. Mazor R, et al. 2018. Proc Natl Acad Sci U S A. 115:E733. PubMed
  20. Karhadkar TR, et al. 2021. J Pharmacol Exp Ther. 376:106. PubMed
  21. Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed
  22. Orecchioni M, et al. 2022. Methods Mol Biol. 2419:779. PubMed
  23. Ma C, et al. 2018. Science. 360:eaan5931. PubMed
  24. Wang Y, et al. 2021. Cancer Cell. 39:1375. PubMed
  25. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  26. Yan J, et al. 2020. Cancer Immunol Res. 8:356. PubMed
  27. Doorduijn EM, et al. 2018. Front Immunol. 0.416666667. PubMed
  28. Silvestre-Roig C, et al. 2019. Nature. 569:236. PubMed
  29. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  30. O'Dea KP, et al. 2020. J Extracell Vesicles. 9:1706708. PubMed
  31. Hilligan KL, et al. 2020. Nat Commun. 11:5637. PubMed
  32. Hofstee MI, et al. 2021. Eur Cell Mater. 41:774. PubMed
  33. Singh PP, et al. 2021. Ocul Surf. 21:271. PubMed
  34. Oba T, et al. 2021. J Immunother Cancer. 9:. PubMed
  35. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  36. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  37. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  38. Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed
  39. Francis M, et al. 2017. Toxicol Sci. 155(1):182-195. PubMed
  40. Lai JF, et al. 2020. J Allergy Clin Immunol. 146:1406. PubMed
  41. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
  42. Enders M, et al. 2020. J Immunol. 204:87. PubMed
  43. Kapellos TS, et al. 2017. Mediators Inflamm. 2017:4315412. PubMed
  44. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  45. Lim CS, et al. 2020. Front Immunol. 11:1186. PubMed
  46. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
  47. Davies CL, et al. 2019. Front Immunol. 10:1048. PubMed
  48. Majer O, et al. 2019. Nature. 575:366. PubMed
  49. Blriot C, et al. 2021. Immunity. :. PubMed
  50. Janela B, et al. 2019. Immunity. 50:1069. PubMed
  51. Zander R, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.077. PubMed
  52. Li J, et al. 2021. Front Immunol. 12:710406. PubMed
  53. Fino KK, et al. 2017. Sci Rep. 5.334722222. PubMed
  54. Ford J, et al. 2019. Front Immunol. 2.502083333. PubMed
  55. Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed
  56. Karmaus PWF, et al. 2019. Nature. 565:101. PubMed
  57. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  58. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  59. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  60. Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed
  61. Qiu Z, et al. 2022. Cancer Discov. 12:502. PubMed
  62. Watson N, et al. 2015. J Immunol. 194:2796. PubMed
  63. Rogers P, Driessnack M, and Schwartz E. 2017. PLoS One. 10.1371/journal.pone.0181985. PubMed
  64. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  65. Udumula MP, et al. 2021. Mol Metab. 53:101272. PubMed
  66. Goltsev Y et al. 2018. Cell. 174(4):968-981 . PubMed
  67. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  68. Zhang C, et al. 2020. Hear Res. 393:107996. PubMed
  69. Winter C, et al. 2018. Cell Metab. 28:175. PubMed
  70. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  71. An Y et al. 2018. Cell reports. 25(3):702-714 . PubMed
  72. Kikuchi K, et al. 2018. J Immunol. 201:635. PubMed
  73. Hofstee MI, et al. 2021. Pathogens. 10:. PubMed
  74. Jones GS, et al. 2020. mSphere. 5:. PubMed
  75. Sun D, et al. 2020. PLoS Pathog. 16:e1008361. PubMed
  76. De Alessandris S, et al. 2019. J Leukoc Biol. 105:1183. PubMed
  77. Wichaiyo S, et al. 2019. Haematologica. 104:1648. PubMed
  78. Li F, et al. 2020. EMBO J. 39:e103205. PubMed
  79. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  80. Blériot C, et al. 2020. Methods Mol Biol. 2164:87. PubMed
  81. Cai S, et al. 2020. Sci Rep. 10:14249. PubMed
  82. Calcagno DM, et al. 2020. Sci Immunol. 5: . PubMed
  83. Valet C, et al. 2022. J Clin Invest. 132: . PubMed
  84. Campisi L, et al. 2022. Nature. 606:945. PubMed
  85. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  86. Hezaveh K, et al. 2022. Immunity. 55:324. PubMed
  87. Potempa M, et al. 2022. J Immunol. 208:1742. PubMed
  88. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
  89. Filippini D, et al. 2019. Sci Rep. 9:12286. PubMed
  90. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  91. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  92. Bajaña S, et al. 2021. Front Immunol. 11:577718. PubMed
  93. Nobs SP, et al. 2021. J Allergy Clin Immunol. . PubMed
  94. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  95. Reglero-Real N, et al. 2021. Immunity. :. PubMed
  96. Mazor R, et al. 2018. Proc Natl Acad Sci U S A. 115:E733. PubMed
  97. Karhadkar TR, et al. 2021. J Pharmacol Exp Ther. 376:106. PubMed
  98. Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed
  99. Orecchioni M, et al. 2022. Methods Mol Biol. 2419:779. PubMed
  100. Ma C, et al. 2018. Science. 360:eaan5931. PubMed
  101. Wang Y, et al. 2021. Cancer Cell. 39:1375. PubMed
  102. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  103. Yan J, et al. 2020. Cancer Immunol Res. 8:356. PubMed
  104. Doorduijn EM, et al. 2018. Front Immunol. 0.416666667. PubMed
  105. Silvestre-Roig C, et al. 2019. Nature. 569:236. PubMed
  106. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  107. O'Dea KP, et al. 2020. J Extracell Vesicles. 9:1706708. PubMed
  108. Hilligan KL, et al. 2020. Nat Commun. 11:5637. PubMed
  109. Hofstee MI, et al. 2021. Eur Cell Mater. 41:774. PubMed
  110. Singh PP, et al. 2021. Ocul Surf. 21:271. PubMed
  111. Oba T, et al. 2021. J Immunother Cancer. 9:. PubMed
  112. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  113. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  114. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  115. Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed
  116. Francis M, et al. 2017. Toxicol Sci. 155(1):182-195. PubMed
  117. Lai JF, et al. 2020. J Allergy Clin Immunol. 146:1406. PubMed
  118. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
  119. Enders M, et al. 2020. J Immunol. 204:87. PubMed
  120. Kapellos TS, et al. 2017. Mediators Inflamm. 2017:4315412. PubMed
  121. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  122. Lim CS, et al. 2020. Front Immunol. 11:1186. PubMed
  123. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
  124. Davies CL, et al. 2019. Front Immunol. 10:1048. PubMed
  125. Majer O, et al. 2019. Nature. 575:366. PubMed
  126. Blriot C, et al. 2021. Immunity. :. PubMed
  127. Janela B, et al. 2019. Immunity. 50:1069. PubMed
  128. Zander R, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.077. PubMed
  129. Li J, et al. 2021. Front Immunol. 12:710406. PubMed
  130. Fino KK, et al. 2017. Sci Rep. 5.334722222. PubMed
  131. Ford J, et al. 2019. Front Immunol. 2.502083333. PubMed
  132. Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed
  133. Karmaus PWF, et al. 2019. Nature. 565:101. PubMed
  134. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  135. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  136. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  137. Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed
  138. Qiu Z, et al. 2022. Cancer Discov. 12:502. PubMed
  139. Watson N, et al. 2015. J Immunol. 194:2796. PubMed
  140. Rogers P, Driessnack M, and Schwartz E. 2017. PLoS One. 10.1371/journal.pone.0181985. PubMed
  141. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  142. Udumula MP, et al. 2021. Mol Metab. 53:101272. PubMed
  143. Goltsev Y et al. 2018. Cell. 174(4):968-981 . PubMed
  144. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  145. Zhang C, et al. 2020. Hear Res. 393:107996. PubMed
  146. Winter C, et al. 2018. Cell Metab. 28:175. PubMed
  147. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  148. An Y et al. 2018. Cell reports. 25(3):702-714 . PubMed
  149. Kikuchi K, et al. 2018. J Immunol. 201:635. PubMed
  150. Hofstee MI, et al. 2021. Pathogens. 10:. PubMed
  151. Jones GS, et al. 2020. mSphere. 5:. PubMed
  152. Sun D, et al. 2020. PLoS Pathog. 16:e1008361. PubMed
  153. De Alessandris S, et al. 2019. J Leukoc Biol. 105:1183. PubMed
  154. Wichaiyo S, et al. 2019. Haematologica. 104:1648. PubMed
RRID
AB_1134213 (BioLegend Cat. No. 128001)
AB_1134214 (BioLegend Cat. No. 128002)

Antigen Details

Structure
14-17 kD protein (134 amino acids), member of the Ly-6 family of GPI linked protein. Ly6 family members share structure homology throughout a distinctive cystein rich protein domain that incorporates O-linked carbohydrates.
Distribution

Ly-6C is expressed primarily on bone marrow myeloid populations, monocytes/macrophages, neutrophils, endothelial cells, and some T cell subsets. Ly-6C is also a marker of memory CD8+ T cells.

Cell Type
Endothelial cells, Macrophages, Monocytes, Neutrophils, T cells
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
2. Cerwenka A, et al. 1998. J. Immunol. 161:97.

Gene ID
17067 View all products for this Gene ID
UniProt
View information about Ly-6C on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All Ly-6C Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-mouse Ly-6C (Maxpar® Ready) HK1.4 FC,CyTOF®
Brilliant Violet 785™ anti-mouse Ly-6C HK1.4 FC
PE/Dazzle™ 594 anti-mouse Ly-6C HK1.4 FC
APC/Fire™ 750 anti-mouse Ly-6C HK1.4 FC
TotalSeq™-A0013 anti-mouse Ly-6C HK1.4 PG
Brilliant Violet 650™ anti-mouse Ly-6C HK1.4 FC
TotalSeq™-C0013 anti-mouse Ly-6C HK1.4 PG
TotalSeq™-B0013 anti-mouse Ly-6C HK1.4 PG
Pacific Blue™ anti-mouse Ly-6C HK1.4 FC
APC anti-mouse Ly-6C HK1.4 FC
Purified anti-mouse Ly-6C HK1.4 FC,IHC-F
Biotin anti-mouse Ly-6C HK1.4 FC
FITC anti-mouse Ly-6C HK1.4 FC
Alexa Fluor® 647 anti-mouse Ly-6C HK1.4 FC
PE anti-mouse Ly-6C HK1.4 FC
PerCP/Cyanine5.5 anti-mouse Ly-6C HK1.4 FC
PE/Cyanine7 anti-mouse Ly-6C HK1.4 FC
Alexa Fluor® 488 anti-mouse Ly-6C HK1.4 FC
Alexa Fluor® 700 anti-mouse Ly-6C HK1.4 FC
APC/Cyanine7 anti-mouse Ly-6C HK1.4 FC
PerCP anti-mouse Ly-6C HK1.4 FC
Brilliant Violet 570™ anti-mouse Ly-6C HK1.4 FC
Brilliant Violet 421™ anti-mouse Ly-6C HK1.4 FC
Brilliant Violet 711™ anti-mouse Ly-6C HK1.4 FC
Brilliant Violet 510™ anti-mouse Ly-6C HK1.4 FC
Brilliant Violet 605™ anti-mouse Ly-6C HK1.4 FC
APC/Fire™ 810 anti-mouse Ly-6C Antibody HK1.4 FC
Spark Red™ 718 anti-mouse Ly-6C HK1.4 FC
PE/Fire™ 810 anti-mouse Ly-6C HK1.4 FC
Spark UV™ 387 anti-mouse Ly-6C HK1.4 FC
Spark Blue™ 550 anti-mouse Ly-6C (Flexi-Fluor™) HK1.4 FC
Spark Blue™ 574 anti-mouse Ly-6C (Flexi-Fluor™) HK1.4 FC
PE/Cyanine5 anti-mouse Ly-6C HK1.4 FC
Spark PLUS B550™ anti-mouse Ly-6C HK1.4 FC
PerCP/Fire™ 806 anti-mouse Ly-6c Antibody HK1.4 FC
Spark YG™ 581 anti-mouse Ly-6C (Flexi-Fluor™) HK1.4 FC
Spark YG™ 593 anti-mouse Ly-6C (Flexi-Fluor™) Antibody HK1.4 FC
Spark NIR™ 685 anti-mouse Ly-6C (Flexi-Fluor™) Antibody HK1.4 FC
StarBright UltraViolet 740 anti-mouse Ly-6C HK1.4 FC
StarBright UltraViolet 795 anti-mouse Ly-6C HK1.4 FC
Spark PLUS UV395™ anti-mouse Ly-6C HK1.4 FC
Go To Top Version: 3    Revision Date: 10/25/2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
HK1.4 (See other available formats)
Regulatory Status
RUO
Other Names
Lymphocyte antigen 6 complex, locus C
Isotype
Rat IgG2c, κ
Ave. Rating
Submit a Review
Product Citations
publications
HK1dot4_Pure_070808.jpg
C57BL/6 mouse bone marrow cells stained with purified HK1.4, followed by anti-rat IgG PE (gated on myeloid cell population)
  • HK1dot4_Pure_070808.jpg
    C57BL/6 mouse bone marrow cells stained with purified HK1.4, followed by anti-rat IgG PE (gated on myeloid cell population)
  • HK1dot4_Pure_Ly6c_Antibody_2_102518
    Fresh, frozen mouse spleen was stained with purified Ly6C clone HK1.4 conjugated and detected with a Cy5 CODEX™ oligonucleotide duplex (red). Samples were counterstained with TCR FITC (green). Data generated at Akoya Biosciences, Inc. using the CODEX™ technology.
Compare all formats
Cat # Size Price Quantity Check Availability Save
128001 50 µg DKK387
Check Availability


Need larger quantities of this item?
Request Bulk Quote
128002 500 µg DKK1396
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Most hematopoietic cells express one or more members of Ly-6 family. The expression of Ly-6 varies with development stage and activation. Ly-6C is a 14-17 kD GPI-linked surface protein expressed on mouse monocyte/macrophage cells, endothelial cells, neutrophils, and some T cell subsets. Ly-6C is reported to be an indicator of memory CD8+ T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
L3 cloned CTL cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F - Verified
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone HK1.4 does not block the binding of clone RB6-8C58.

Additional reported applications (for relevant formats of this clone) include: in vitro activation of T cells1-3 and immunohistochemistry of frozen sections4.

Application References
  1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (Activ)
  2. Herold KC, et al. 1990. Diabetes 39:815. (Activ)
  3. Havran WL, et al. 1988. J. Immunol. 140:1034 (Activ)
  4. Flanagan K, et al. 2008. J. Immunol. 180:3874. (IHC)
  5. Makaroff LE, et al. 2009. P. Natl. Acad. Sci. USA 106:4799. (FC)
  6. Zuber J, et al. 2009. Genes Dev. 23:877. (FC) PubMed
  7. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  8. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  9. Watson NB, et al. 2015. J Immunol. 194:2796. PubMed
Product Citations
  1. Li F, et al. 2020. EMBO J. 39:e103205. PubMed
  2. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  3. Blériot C, et al. 2020. Methods Mol Biol. 2164:87. PubMed
  4. Cai S, et al. 2020. Sci Rep. 10:14249. PubMed
  5. Calcagno DM, et al. 2020. Sci Immunol. 5: . PubMed
  6. Valet C, et al. 2022. J Clin Invest. 132: . PubMed
  7. Campisi L, et al. 2022. Nature. 606:945. PubMed
  8. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  9. Hezaveh K, et al. 2022. Immunity. 55:324. PubMed
  10. Potempa M, et al. 2022. J Immunol. 208:1742. PubMed
  11. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
  12. Filippini D, et al. 2019. Sci Rep. 9:12286. PubMed
  13. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  14. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  15. Bajaña S, et al. 2021. Front Immunol. 11:577718. PubMed
  16. Nobs SP, et al. 2021. J Allergy Clin Immunol. . PubMed
  17. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  18. Reglero-Real N, et al. 2021. Immunity. :. PubMed
  19. Mazor R, et al. 2018. Proc Natl Acad Sci U S A. 115:E733. PubMed
  20. Karhadkar TR, et al. 2021. J Pharmacol Exp Ther. 376:106. PubMed
  21. Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed
  22. Orecchioni M, et al. 2022. Methods Mol Biol. 2419:779. PubMed
  23. Ma C, et al. 2018. Science. 360:eaan5931. PubMed
  24. Wang Y, et al. 2021. Cancer Cell. 39:1375. PubMed
  25. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  26. Yan J, et al. 2020. Cancer Immunol Res. 8:356. PubMed
  27. Doorduijn EM, et al. 2018. Front Immunol. 0.416666667. PubMed
  28. Silvestre-Roig C, et al. 2019. Nature. 569:236. PubMed
  29. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  30. O'Dea KP, et al. 2020. J Extracell Vesicles. 9:1706708. PubMed
  31. Hilligan KL, et al. 2020. Nat Commun. 11:5637. PubMed
  32. Hofstee MI, et al. 2021. Eur Cell Mater. 41:774. PubMed
  33. Singh PP, et al. 2021. Ocul Surf. 21:271. PubMed
  34. Oba T, et al. 2021. J Immunother Cancer. 9:. PubMed
  35. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  36. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  37. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  38. Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed
  39. Francis M, et al. 2017. Toxicol Sci. 155(1):182-195. PubMed
  40. Lai JF, et al. 2020. J Allergy Clin Immunol. 146:1406. PubMed
  41. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
  42. Enders M, et al. 2020. J Immunol. 204:87. PubMed
  43. Kapellos TS, et al. 2017. Mediators Inflamm. 2017:4315412. PubMed
  44. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  45. Lim CS, et al. 2020. Front Immunol. 11:1186. PubMed
  46. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
  47. Davies CL, et al. 2019. Front Immunol. 10:1048. PubMed
  48. Majer O, et al. 2019. Nature. 575:366. PubMed
  49. Blriot C, et al. 2021. Immunity. :. PubMed
  50. Janela B, et al. 2019. Immunity. 50:1069. PubMed
  51. Zander R, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.077. PubMed
  52. Li J, et al. 2021. Front Immunol. 12:710406. PubMed
  53. Fino KK, et al. 2017. Sci Rep. 5.334722222. PubMed
  54. Ford J, et al. 2019. Front Immunol. 2.502083333. PubMed
  55. Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed
  56. Karmaus PWF, et al. 2019. Nature. 565:101. PubMed
  57. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  58. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  59. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  60. Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed
  61. Qiu Z, et al. 2022. Cancer Discov. 12:502. PubMed
  62. Watson N, et al. 2015. J Immunol. 194:2796. PubMed
  63. Rogers P, Driessnack M, and Schwartz E. 2017. PLoS One. 10.1371/journal.pone.0181985. PubMed
  64. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  65. Udumula MP, et al. 2021. Mol Metab. 53:101272. PubMed
  66. Goltsev Y et al. 2018. Cell. 174(4):968-981 . PubMed
  67. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  68. Zhang C, et al. 2020. Hear Res. 393:107996. PubMed
  69. Winter C, et al. 2018. Cell Metab. 28:175. PubMed
  70. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  71. An Y et al. 2018. Cell reports. 25(3):702-714 . PubMed
  72. Kikuchi K, et al. 2018. J Immunol. 201:635. PubMed
  73. Hofstee MI, et al. 2021. Pathogens. 10:. PubMed
  74. Jones GS, et al. 2020. mSphere. 5:. PubMed
  75. Sun D, et al. 2020. PLoS Pathog. 16:e1008361. PubMed
  76. De Alessandris S, et al. 2019. J Leukoc Biol. 105:1183. PubMed
  77. Wichaiyo S, et al. 2019. Haematologica. 104:1648. PubMed
  78. Li F, et al. 2020. EMBO J. 39:e103205. PubMed
  79. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  80. Blériot C, et al. 2020. Methods Mol Biol. 2164:87. PubMed
  81. Cai S, et al. 2020. Sci Rep. 10:14249. PubMed
  82. Calcagno DM, et al. 2020. Sci Immunol. 5: . PubMed
  83. Valet C, et al. 2022. J Clin Invest. 132: . PubMed
  84. Campisi L, et al. 2022. Nature. 606:945. PubMed
  85. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  86. Hezaveh K, et al. 2022. Immunity. 55:324. PubMed
  87. Potempa M, et al. 2022. J Immunol. 208:1742. PubMed
  88. Hailemichael Y, et al. 2022. Cancer Cell. 40:509. PubMed
  89. Filippini D, et al. 2019. Sci Rep. 9:12286. PubMed
  90. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  91. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  92. Bajaña S, et al. 2021. Front Immunol. 11:577718. PubMed
  93. Nobs SP, et al. 2021. J Allergy Clin Immunol. . PubMed
  94. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  95. Reglero-Real N, et al. 2021. Immunity. :. PubMed
  96. Mazor R, et al. 2018. Proc Natl Acad Sci U S A. 115:E733. PubMed
  97. Karhadkar TR, et al. 2021. J Pharmacol Exp Ther. 376:106. PubMed
  98. Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed
  99. Orecchioni M, et al. 2022. Methods Mol Biol. 2419:779. PubMed
  100. Ma C, et al. 2018. Science. 360:eaan5931. PubMed
  101. Wang Y, et al. 2021. Cancer Cell. 39:1375. PubMed
  102. Jackson JW, et al. 2021. Mol Ther Oncolytics. 22:444. PubMed
  103. Yan J, et al. 2020. Cancer Immunol Res. 8:356. PubMed
  104. Doorduijn EM, et al. 2018. Front Immunol. 0.416666667. PubMed
  105. Silvestre-Roig C, et al. 2019. Nature. 569:236. PubMed
  106. Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed
  107. O'Dea KP, et al. 2020. J Extracell Vesicles. 9:1706708. PubMed
  108. Hilligan KL, et al. 2020. Nat Commun. 11:5637. PubMed
  109. Hofstee MI, et al. 2021. Eur Cell Mater. 41:774. PubMed
  110. Singh PP, et al. 2021. Ocul Surf. 21:271. PubMed
  111. Oba T, et al. 2021. J Immunother Cancer. 9:. PubMed
  112. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  113. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  114. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  115. Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed
  116. Francis M, et al. 2017. Toxicol Sci. 155(1):182-195. PubMed
  117. Lai JF, et al. 2020. J Allergy Clin Immunol. 146:1406. PubMed
  118. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
  119. Enders M, et al. 2020. J Immunol. 204:87. PubMed
  120. Kapellos TS, et al. 2017. Mediators Inflamm. 2017:4315412. PubMed
  121. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  122. Lim CS, et al. 2020. Front Immunol. 11:1186. PubMed
  123. Lee JY, et al. 2018. Front Immunol. 0.678472222. PubMed
  124. Davies CL, et al. 2019. Front Immunol. 10:1048. PubMed
  125. Majer O, et al. 2019. Nature. 575:366. PubMed
  126. Blriot C, et al. 2021. Immunity. :. PubMed
  127. Janela B, et al. 2019. Immunity. 50:1069. PubMed
  128. Zander R, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.10.077. PubMed
  129. Li J, et al. 2021. Front Immunol. 12:710406. PubMed
  130. Fino KK, et al. 2017. Sci Rep. 5.334722222. PubMed
  131. Ford J, et al. 2019. Front Immunol. 2.502083333. PubMed
  132. Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed
  133. Karmaus PWF, et al. 2019. Nature. 565:101. PubMed
  134. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  135. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  136. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  137. Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed
  138. Qiu Z, et al. 2022. Cancer Discov. 12:502. PubMed
  139. Watson N, et al. 2015. J Immunol. 194:2796. PubMed
  140. Rogers P, Driessnack M, and Schwartz E. 2017. PLoS One. 10.1371/journal.pone.0181985. PubMed
  141. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  142. Udumula MP, et al. 2021. Mol Metab. 53:101272. PubMed
  143. Goltsev Y et al. 2018. Cell. 174(4):968-981 . PubMed
  144. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  145. Zhang C, et al. 2020. Hear Res. 393:107996. PubMed
  146. Winter C, et al. 2018. Cell Metab. 28:175. PubMed
  147. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  148. An Y et al. 2018. Cell reports. 25(3):702-714 . PubMed
  149. Kikuchi K, et al. 2018. J Immunol. 201:635. PubMed
  150. Hofstee MI, et al. 2021. Pathogens. 10:. PubMed
  151. Jones GS, et al. 2020. mSphere. 5:. PubMed
  152. Sun D, et al. 2020. PLoS Pathog. 16:e1008361. PubMed
  153. De Alessandris S, et al. 2019. J Leukoc Biol. 105:1183. PubMed
  154. Wichaiyo S, et al. 2019. Haematologica. 104:1648. PubMed
RRID
AB_1134213 (BioLegend Cat. No. 128001)
AB_1134214 (BioLegend Cat. No. 128002)

Antigen Details

Structure
14-17 kD protein (134 amino acids), member of the Ly-6 family of GPI linked protein. Ly6 family members share structure homology throughout a distinctive cystein rich protein domain that incorporates O-linked carbohydrates.
Distribution

Ly-6C is expressed primarily on bone marrow myeloid populations, monocytes/macrophages, neutrophils, endothelial cells, and some T cell subsets. Ly-6C is also a marker of memory CD8+ T cells.

Cell Type
Endothelial cells, Macrophages, Monocytes, Neutrophils, T cells
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
2. Cerwenka A, et al. 1998. J. Immunol. 161:97.

Gene ID
17067 View all products for this Gene ID
UniProt
View information about Ly-6C on UniProt.org

Other Formats

View All Ly-6C Reagents Request Custom Conjugation
Description Clone Applications
Purified anti-mouse Ly-6C (Maxpar® Ready) HK1.4 FC,CyTOF®
Brilliant Violet 785™ anti-mouse Ly-6C HK1.4 FC
PE/Dazzle™ 594 anti-mouse Ly-6C HK1.4 FC
APC/Fire™ 750 anti-mouse Ly-6C HK1.4 FC
TotalSeq™-A0013 anti-mouse Ly-6C HK1.4 PG
Brilliant Violet 650™ anti-mouse Ly-6C HK1.4 FC
TotalSeq™-C0013 anti-mouse Ly-6C HK1.4 PG
TotalSeq™-B0013 anti-mouse Ly-6C HK1.4 PG
Pacific Blue™ anti-mouse Ly-6C HK1.4 FC
APC anti-mouse Ly-6C HK1.4 FC
Purified anti-mouse Ly-6C HK1.4 FC,IHC-F
Biotin anti-mouse Ly-6C HK1.4 FC
FITC anti-mouse Ly-6C HK1.4 FC
Alexa Fluor® 647 anti-mouse Ly-6C HK1.4 FC
PE anti-mouse Ly-6C HK1.4 FC
PerCP/Cyanine5.5 anti-mouse Ly-6C HK1.4 FC
PE/Cyanine7 anti-mouse Ly-6C HK1.4 FC
Alexa Fluor® 488 anti-mouse Ly-6C HK1.4 FC
Alexa Fluor® 700 anti-mouse Ly-6C HK1.4 FC
APC/Cyanine7 anti-mouse Ly-6C HK1.4 FC
PerCP anti-mouse Ly-6C HK1.4 FC
Brilliant Violet 570™ anti-mouse Ly-6C HK1.4 FC
Brilliant Violet 421™ anti-mouse Ly-6C HK1.4 FC
Brilliant Violet 711™ anti-mouse Ly-6C HK1.4 FC
Brilliant Violet 510™ anti-mouse Ly-6C HK1.4 FC
Brilliant Violet 605™ anti-mouse Ly-6C HK1.4 FC
APC/Fire™ 810 anti-mouse Ly-6C Antibody HK1.4 FC
Spark Red™ 718 anti-mouse Ly-6C HK1.4 FC
PE/Fire™ 810 anti-mouse Ly-6C HK1.4 FC
Spark UV™ 387 anti-mouse Ly-6C HK1.4 FC
Spark Blue™ 550 anti-mouse Ly-6C (Flexi-Fluor™) HK1.4 FC
Spark Blue™ 574 anti-mouse Ly-6C (Flexi-Fluor™) HK1.4 FC
PE/Cyanine5 anti-mouse Ly-6C HK1.4 FC
Spark PLUS B550™ anti-mouse Ly-6C HK1.4 FC
PerCP/Fire™ 806 anti-mouse Ly-6c Antibody HK1.4 FC
Spark YG™ 581 anti-mouse Ly-6C (Flexi-Fluor™) HK1.4 FC
Spark YG™ 593 anti-mouse Ly-6C (Flexi-Fluor™) Antibody HK1.4 FC
Spark NIR™ 685 anti-mouse Ly-6C (Flexi-Fluor™) Antibody HK1.4 FC
StarBright UltraViolet 740 anti-mouse Ly-6C HK1.4 FC
StarBright UltraViolet 795 anti-mouse Ly-6C HK1.4 FC
Spark PLUS UV395™ anti-mouse Ly-6C HK1.4 FC
Go To Top Version: 3    Revision Date: 10/25/2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account